Search results
Results from the WOW.Com Content Network
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [ 5 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .
Luspatercept is a TGFβ ligand that acts to decrease SMAD2 and SMAD3 signaling involved in erythropoeisis and may be used in MDS with anemia that is not responsive to erythrocyte stimulating agents or mild MDS with ring sideroblasts. Luspatercept was shown to decrease the need for transfusions and this effect lasted for a median of 30.6 weeks.
Darbepoetin alfa / d ɑːr b ə ˈ p oʊ ɪ t ɪ n / is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition.
Mycophenolic acid is an immunosuppressant medication used to prevent rejection following organ transplantation and to treat autoimmune conditions such as Crohn's disease and lupus.
Asunercept blocks the CD95–ligand from binding to the CD95-receptor (CD95), which induces apoptosis.In oncology, this blockade is intended to prevent the killing of activated T cells [7] that can be induced by tumor-associated macrophages (TAMs), [8] endothelial cells, [9] or fibroblasts.
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. [2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).
Lipoglycopeptides are a class of antibiotic that have lipophilic side-chains linked to glycopeptides.The class includes oritavancin, telavancin and dalbavancin. [1] [2]In September 2009 the US Food and Drug Administration (FDA) approved telavancin (Vibativ) for complicated skin and skin structure infections (cSSSI) On May 23, 2014, the FDA approved dalbavancin (Dalvance), an injectable drug ...
Netupitant is a selective NK 1 receptor antagonist. [6]Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity of the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which ...